This is groundbreaking news, Dr
Carry the 2025 ADA Diabetes caveat too: HPA axis activation alone does not explain GLP-1 non-response in type 2 diabetes
This typically requires BMI of 30 or higher (or 27 with comorbidities), absence of contraindications, willingness to attend regular study visits, and acceptance of randomization (you might receive placebo)
Both options require multiple sessions depending on treatment goals, but providers should consider cost transparency , session planning , and patient expectations when recommending one over the other
The before-and-after for this group is measured in blood panels as much as photographs
But the results tend to be more durable because the underlying metabolic drivers have changed, not just suppressed